SCHEMBL6479263

SCHEMBL6479263

COc1cc(Nc2ncnc(Cl)n2)cc(OC)c1OCCN1CCOCC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.57
KDR P35968 5/20 0.48
SRC P12931 4/20 0.48
LCK P06239 2/20 0.48
MAPK14 Q16539 1/20 0.48
EPHB4 P54760 3/20 0.48
EPHA2 P29317 1/20 0.48
EGFR P00533 4/20 0.46
CYP2D6 P10635 1/20 0.46
TSHR P16473 1/20 0.46
FGFR1 P11362 1/20 0.44
FLT1 P17948 1/20 0.44
FLT4 P35916 1/20 0.44
FGFR3 P22607 1/20 0.44
ABL1 P00519 1/20 0.42
BCR P11274 1/20 0.42
ZAP70 P43403 1/20 0.42
JAK3 P52333 1/20 0.42
BTK Q06187 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6482909 0.94 SRC (0.52) SYKKDRSRCLCKMAPK14
SCHEMBL6483193 0.88 KDR (0.57) KDRSRCLCKMAPK14EPHB4
SCHEMBL6479290 0.86 EPHB4 (0.50) KDRSRCLCKEPHB4EGFR
SCHEMBL6493240 0.82 KDR (0.56) SYKKDRSRCLCKMAPK14
SCHEMBL6488784 0.78 EPHB4 (0.45) KDRSRCEPHB4EGFRFGFR1
SCHEMBL4946510 0.77 EPHB4 (0.69) KDRLCKMAPK14EPHB4EGFR
SCHEMBL6479597 0.77 KDR (0.57) KDRSRCLCKMAPK14EPHB4
SCHEMBL4712159 0.74 SMG1 (0.57) SYKKDRSRCLCKMAPK14
SCHEMBL6999575 0.74 FYN (0.58) SYKKDRSRCLCKMAPK14
SCHEMBL10196165 0.73 SYK (1.00) SYKCYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6864255-B2 Substituted triazinyl amide derivatives and methods of use AMGEN INC. (US) 2005-03-08 US disclosed
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use AMGEN INC. 2003-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030087908-A1 Substituted triazinyl amide derivatives and methods of use FLT4, FLT1, VEGFA SYK 1232/4885KDR 4/4885SRC 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.